Ra Capital Management, L.P. Larimar Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $6.64 Billion
- Q2 2024
A detailed history of Ra Capital Management, L.P. transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 6,045,351 shares of LRMR stock, worth $46.8 Million. This represents 0.66% of its overall portfolio holdings.
Number of Shares
6,045,351Holding current value
$46.8 Million% of portfolio
0.66%Shares
6 transactions
Others Institutions Holding LRMR
# of Institutions
115Shares Held
67.6MCall Options Held
290KPut Options Held
38.9K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$164 Million3.23% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$33.9 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.33MShares$33.5 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.86MShares$29.9 Million11.62% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$26.4 Million6.65% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $335M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...